ARCA biopharma develops genetically-targeted therapies for cardiovascular diseases, such as COVID-19 treatment Recombinant Nematode Anticoagulant Protein c2 and Gencaro, which is used to treat atrial fibrillation in heart failure patients. They have partnerships with LabCorp to develop a genetic test for their GENETIC-AF clinical trial, and with Colorado Prevention Center to develop and market Gencaro. Founded in 2004, ARCA biopharma is based in Westminster, Colorado.